NXEN (Nexien BioPharma) Total Stockholders Equity: $-0.45 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nexien BioPharma Total Stockholders Equity?

Nexien BioPharma NXEN Total Stockholders Equity is $-0.45 Mil as of Mar. 2025.

Nexien BioPharma's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $-0.45 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Nexien BioPharma's Book Value per Share for the quarter that ended in Mar. 2025 was $-0.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Nexien BioPharma's Debt-to-Equity for the quarter that ended in Mar. 2025 was -0.83.

Nexien BioPharma  (OTCPK:NXEN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Nexien BioPharma's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-0.451-0)/70.772
=-0.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Nexien BioPharma's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.375 + 0) / -0.451
=-0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexien BioPharma Total Stockholders Equity Related Terms

Nexien BioPharma Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Nexien BioPharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexien BioPharma Total Stockholders Equity Chart

Nexien BioPharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Stockholders Equity
Get a 7-Day Free Trial -0.01 -0.01 -0.12 -0.25 -0.36

Nexien BioPharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.36 -0.39 -0.42 -0.45
What does a Total Stockholders Equity of $-0.45 Mil mean?
Nexien BioPharma (NXEN) has a Total Stockholders Equity of $-0.45 Mil as of Mar. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Nexien BioPharma and its competitors.
Is Nexien BioPharma's Total Stockholders Equity too high?
Nexien BioPharma's current Total Stockholders Equity is $-0.45 Mil.
How does Nexien BioPharma's Total Stockholders Equity compare to FLHLF and ZTS?
Nexien BioPharma's Total Stockholders Equity of $-0.45 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Nexien BioPharma and its competitors. Nexien BioPharma's current Total Stockholders Equity is $-0.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexien BioPharma stock overvalued right now?
Nexien BioPharma (NXEN) has a current Total Stockholders Equity of $-0.45 Mil. The current Total Stockholders Equity is $-0.45 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Nexien BioPharma (NXEN), the current Total Stockholders Equity is $-0.45 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nexien BioPharma Business Description

Address 4340 East Kentucky Avenue, Suite 206, Glendale, CO, USA, 80246
Nexien BioPharma Inc is engaged in pre-clinical and drug development activities, by U.S. Food and Drug Administration (FDA) protocols, for certain pharmaceutical formulations that include cannabinoids. The company is pursuing the formulation and development of drugs containing cannabinoids for the treatment of various diseases, disorders, and medical conditions.